Premium
Rybelsus: an oral formulation of the GLP ‐1 agonist semaglutide
Author(s) -
Chaplin Steve
Publication year - 2020
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1873
Subject(s) - semaglutide , medicine , agonist , type 2 diabetes , adverse effect , pharmacology , diabetes mellitus , endocrinology , receptor , liraglutide
Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects.